Response to: 'Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences' by Shah.

Emery, Paul; Vencovský, Jirí; Ghil, Jeehoon; Kang, Jung Won

Emery, Paul; Vencovský, Jirí; Ghil, Jeehoon; Kang, Jung Won.

Afiliação

Emery P; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Vencovský J; Institute of Rheumatology, Prague, Czech Republic.
Ghil J; Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.
Kang JW; Samsung Bioepis Co., Ltd., Incheon, Republic of Korea.

Ann Rheum Dis ; 75(9): e61, 2016 09.

Article em En | MEDLINE | ID: mdl-27435063

Assuntos

Medicamentos Biossimilares; Etanercepte; Anticorpos Monoclonais; Antirreumáticos; Imunoglobulina G; Receptores do Fator de Necrose Tumoral

Palavras-chave

Disease Activity; Inflammation; Treatment

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicamentos Biossimilares / Etanercepte Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google